Skip to main content

Catalyst Calendar

Scope

Mon, Oct 5, 2026

1 updates
GMAB
2:49 PM

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline

Trial Results • Phase 3Phase 3 EPCORE DLBCL-2 topline results Mon, Oct 5, 2026genmab.com

Sat, Oct 3, 2026

1 updates
GMAB
3:40 PM

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Media Release COPENHAGEN, Denmark; October 3, 2026 Treatment with Rina-S ® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC) Antitumor activity was

Trial Results • Phase 1/2IGCS late-breaking oral presentation of RAINFOL-01 Part C results Sat, Oct 3, 2026genmab.com

Fri, Oct 2, 2026

1 updates
GMAB
1:50 PM

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28,

genmab.com

Tue, Sep 29, 2026

1 updates
GMAB
9:32 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated September 24,2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate

genmab.com

Thu, Sep 24, 2026

1 updates

Wed, Sep 9, 2026

1 updates
GMAB
9:37 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated September 8, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate

genmab.com

Tue, Sep 8, 2026

2 updates
GMAB
2:44 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,011 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or

genmab.com
GMAB
6:00 AM

Notice to Convene an Extraordinary General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold an Extraordinary General Meeting on Wednesday, October 7, 2026 COPENHAGEN, Denmark; September 8, 2026 – Genmab A/S (Nasdaq: GMAB) convenes an Extraordinary General Meeting to be held on Wednesday, October 7, 2026, at 3:00 PM CEST at Genmab's offices, Carl

genmab.com

Tue, Aug 25, 2026

1 updates
GMAB
9:00 AM

Genmab to Participate in Upcoming Investor Conferences

Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference in Boston on September

genmab.com

Wed, Aug 12, 2026

1 updates
GMAB
9:32 AM

Genmab A/S has published its Articles of Association

Genmab A/S has published its Articles of Association dated August 11, 2026. The Articles of Association can be found on Genmab’s website: https://ir.genmab.com/genmab-news Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

genmab.com

Tue, Aug 11, 2026

1 updates
GMAB
1:54 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or

genmab.com

Thu, Aug 6, 2026

1 updates
GMAB
11:02 AM

Genmab Announces Financial Results for the First Half of 2026

August 6, 2026 Copenhagen, Denmark; Interim Report for the Six Months Ended June 30, 2026 Highlights Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), demonstrating statistically significant

genmab.com

Thu, Jul 23, 2026

1 updates
GMAB
4:00 PM

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE ® DLBCL-1 trial and was not met Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the

Trial Results • Phase 3Results event Thu, Jul 23, 2026genmab.com

Wed, Jul 15, 2026

1 updates